Effects of carbendazim and astaxanthin co-treatment on the proliferation of MCF-7 breast cancer cells

Basit Öğe Kaydı
dc.contributor.authorAtalay, Pinar Buket
dc.contributor.authorKuku, Gamze
dc.contributor.authorTuna, Bilge Guvenc
dc.date.accessioned2024-07-12T21:47:29Z
dc.date.available2024-07-12T21:47:29Z
dc.date.issued2019en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractThere has been a controversy in the oncology field about the use of antioxidants along with chemotherapeutics in cancer treatment. This study aimed to investigate the effects of a potent antioxidant (astaxanthin) co-treatment with a promising anti-cancer drug (carbendazim), which is in phase I clinical trials, on MCF-7 breast cancer cell proliferation. MCF-7 cells were treated with carbendazim, astaxanthin, or their combinations and incubated for 24h. After the incubation, each treatment group was evaluated for proliferation, cell cycle progression, and production of reactive oxygen species (ROS) using WST-1, flow cytometry, and CM-H2DCFDA, respectively. All tested carbendazim and astaxanthin combinations increased the anti-proliferative effect of Carb treatment alone and increased the G2/M phase cell cycle arrest compared to the DMSO-treated control. Astaxanthin, at all concentrations tested, reduced the elevated intracellular ROS levels induced by the carbendazim treatment. Our data suggest that astaxanthin and carbendazim co-treatment enhances the anti-proliferative effect of carbendazim as a single agent, while alleviating the carbendazim treatment-associated ROS production in MCF-7 cells. These findings may contribute to the current debate on the use of antioxidants along with anti-cancer drugs in cancer chemotherapy.en_US
dc.identifier.doi10.1007/s11626-018-0312-0
dc.identifier.endpage119en_US
dc.identifier.issn1071-2690
dc.identifier.issn1543-706X
dc.identifier.issue2en_US
dc.identifier.pmid30547284en_US
dc.identifier.scopus2-s2.0-85058467330en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage113en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s11626-018-0312-0
dc.identifier.urihttps://hdl.handle.net/20.500.12415/8047
dc.identifier.volume55en_US
dc.identifier.wosWOS:000458521700005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofIN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMALen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY01226
dc.subjectMCF-7en_US
dc.subjectBreast canceren_US
dc.subjectCarbendazimen_US
dc.subjectAstaxanthinen_US
dc.titleEffects of carbendazim and astaxanthin co-treatment on the proliferation of MCF-7 breast cancer cellsen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu